Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)

NCT05263193 · clinicaltrials.gov ↗

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Immune-mediated Thrombocytopenic Purpura

Interventions

DRUG: Caplacizumab

Sponsor

Sanofi